
News|Articles|July 1, 2002
Liver toxicity risk low with rosiglitazone
Ever since troglitazone was pulled from the market because of hepatotoxicity,clinicians has been concerned that this may be a class effect. But a newstudy of rosiglitazone (Avandia), funded by manufacturer SmithKlineBeecham,indicates this drug is not associated with heptatotoxic effects.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
How PBMs are tackling behavioral health
3
Most commercial plans cover SC and IV oncology therapies at parity
4
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
5































